Impact of Tumor Necrosis Factor Inhibition on Healthcare Costs in Patients with Rheumatoid Arthritis.

被引：0
|
作者：
Maksymowych, Walter P. [1 ]
Nguen Xuan Thanh [2 ]
Homik, Joanne [1 ]
Barnabe, Cheryl C. M. [1 ]
Martin, Liam [1 ]
Barr, Susan G. [1 ]
Ohinmaa, Arto [1 ]
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Inst Hlth Econ, Edmonton, AB, Canada
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
448
引用
收藏
页码：S171 / S171
页数：1
相关论文
共 50 条
  • [1] Impact of Severity Index for Rheumatoid Arthritis On Healthcare Costs and Utilizations in Patients with Rheumatoid Arthritis.
    Baser, Onur
    Wang, Li
    Du, Juan
    Wang, Hai
    Xie, Lin
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S908 - S908
  • [2] Tumor necrosis factor blockers in rheumatoid arthritis.
    Pisetsky, DS
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (11): : 810 - 811
  • [3] Polymorphisms of tumor necrosis factor receptor I and II in patients with rheumatoid arthritis.
    Kaijzel, EL
    Bakker, AM
    van Krugten, MV
    Huizinga, TWJ
    Breedveld, FC
    Verweij, CL
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S194 - S194
  • [4] Association of tumor necrosis factor α 5′-flanking region polymorphism with Japanese patients with rheumatoid arthritis.
    Ichikawa, N
    Kotake, S
    Hakoda, M
    Higami, K
    Kawasaki, H
    Tsuchiya, N
    Tokunaga, K
    Kamatani, N
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S71 - S71
  • [5] Weight gain associated with the administration of tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis.
    Fonseca, JE
    Canhao, H
    Cruz, M
    Valério, B
    Castelao, W
    Mesquita, T
    Resende, C
    Macieira, C
    da Silva, JAP
    Branco, J
    Queiroz, MV
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S170 - S170
  • [6] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
    Genovese, MC
    Becker, J
    Schiff, M
    Luggen, M
    Sherrer, Y
    Kremer, J
    Birbara, C
    Box, J
    Natarajan, K
    Nuamah, I
    Li, T
    Aranda, R
    Hagerty, DT
    Dougados, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11): : 1114 - 1123
  • [7] Comparison of healthcare costs in patients with rheumatoid arthritis who received anti-tumor necrosis factor treatment with or without methotrexate
    Tang, B.
    Dabbous, O.
    Rahman, M.
    Meissner, B.
    Thompson, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 275 - 275
  • [8] Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.
    Setoguchi, S.
    Schneeweiss, S.
    Avorn, J.
    Katz, J. N.
    Weinblatt, M. E.
    Levin, R.
    Solomon, D. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S38 - S38
  • [9] Reduced Cardiovascular Risk with Use of Methotrexate and Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis.
    Bozaite-Gluosniene, Rasa
    Tang, Xiaoqin
    Kirchner, H. Lester
    Antohe, Jana L.
    Morris, Stephanie J.
    Wasko, Mary Chester
    Bili, Androniki
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S279 - S280
  • [10] Anti-tumor necrosis factor therapy with infliximab decreases the risk of stroke in patients with rheumatoid arthritis.
    Wolfe, F
    Nadareishvili, ZG
    Hallenbeck, JM
    Michaud, K
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4099 - 4099
12345